Disruptor 50: No. 29 Intarcia Therapeutics By: CNBC.com News May 12, 2015 at 07:00 AM EDT Investors believe Intarcia's drug-delivery system could very well upend the $55 billion worldwide market for treating Type-2 diabetes. Read More >> Related Stocks: Merck & Co Novartis Ag ADR